Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?

Journal of Feline Medicine and Surgery

Volumn 17, Issue 11, 2015, Pages 925-939

  Hartmann, Katrin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FELINE LEUKEMIA VIRUS VACCINE; ONCOPROTEIN; VIRUS VACCINE;

ANIMAL; CAT; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FELINE IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; PATHOLOGY; PRACTICE GUIDELINE; VACCINATION; VETERINARY;

ANIMALS; ANTIVIRAL AGENTS; CATS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; PRACTICE GUIDELINES AS TOPIC; RETROVIRIDAE PROTEINS, ONCOGENIC; VACCINATION; VIRAL VACCINES;

EID: 84945125187     PISSN: 1098612X     EISSN: 15322750     Source Type: Journal    
DOI: 10.1177/1098612X15610676     Document Type: Review

References (122)

1. M.J.HosieD.AddieS.Belak. Feline immunodeficiency. ABCD guidelines on prevention and management. J Feline Med Surg2009; 11: 575–584.
2. H.LutzD.AddieS.Belak. Feline leukaemia. ABCD guidelines on prevention and management. J Feline Med Surg2009; 11: 565–574.
3. R.K.SellonK.Hartmann. Feline immunodeficiency virus infection. In: C.E.Greene (ed). Infectious diseases of the dog and cat. 4th ed.St Louis, MO: Elsevier Saunders, 2012, pp 136–149.
4. K.Hartmann. Antiviral and immunomodulatory chemotherapy. In: C.E.Greene (ed). Infectious diseases of the dog and cat. 4th ed.St Louis, MO: Elsevier Saunders, 2012, pp 10–24.
5. K.Hartmann. Feline leukemia virus infection. In: C.E.Greene (ed). Infectious diseases of the dog and cat. 4th ed.St Louis, MO: Elsevier Saunders, 2012, pp 108–136.
6. S.E.GleichS.KriegerK.Hartmann. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany. J Feline Med Surg2009; 11: 985–992.
7. D.D.AddieJ.M.DennisS.Toth. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet Rec2000; 146: 419–424.
8. J.LevyC.CrawfordK.Hartmann. 2008American Association of Feline Practitioners’ feline retrovirus management guidelines. J Feline Med Surg2008; 10: 300–316.
9. K.Hartmann. Clinical aspects of feline immunodeficiency and feline leukemia virus infection. Vet Immunol Immunopathol2011; 143: 190–201.
10. K.Hartmann. Clinical aspects of feline retroviruses: a review. Viruses2012; 4: 2684–2710.
11. E.De Clercq. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem1995; 38: 2491–2517.
12. E.De Clercq. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents2009; 33: 307–320.
13. L.PalmisanoS.Vella. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita2011; 47: 44–48.
14. J.AuwerxR.EsnoufE.De Clercq. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol Pharmacol2004; 65: 244–251.
15. S.RavichandranR.VeerasamyS.Raman. An overview on HIV-1 reverse transcriptase inhibitors. Dig J Nanomater Biostruct2008; 3: 171–187.
16. H.MohammadiD.Bienzle. Pharmacological inhibition of feline immunodeficiency virus (FIV). Viruses2012; 4: 708–724.
17. R.TresslerC.Godfrey. NRTI backbone in HIV treatment: will it remain relevant?Drugs2012; 72: 2051–2062.
18. E.De Clercq. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv Pharmacol2013; 67: 317–358.
19. J.P.HorwitzJ.ChuaM.Noel. Nucleosides. V. The monomesylates of 1-(2′-deoxy-B-D-lyxofuranosyl)thymine. J Org Chem1964; 29: 2076–2078.
20. H.MitsuyaK.J.WeinholdP.A.Furman. 3′-azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA1985; 82: 7096–7100.
21. C.Ezzell. AZT given the green light for clinical treatment of AIDS. Nature1987; 326: 430.
22. K.HartmannA.DonathW.Kraft. AZT in the treatment of feline immunodeficiency virus infection: part 2. Feline Pract1995; 23(6): 13–20.
23. K.HartmannA.DonathW.Kraft. AZT in the treatment of feline immunodeficiency virus infection: part 1. Feline Pract1995; 23(5): 16–21.
24. L.R.BissetH.LutzJ.Boni. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Res2002; 53: 35–45.
25. J.M.GobertK.M.RemingtonY.Q.Zhu. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2′,3′-dideoxyinosine alone and in combination with 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother1994; 38: 861–864.
26. M.A.McCrackin StevensonD.G.McBroom. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. Am J Vet Res2001; 62: 588–594.
27. T.W.NorthG.L.NorthN.C.Pedersen. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother1989; 33: 915–919.
28. K.M.RemingtonB.ChesebroK.Wehrly. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J Virol1991; 65: 308–312.
29. K.M.RemingtonY.Q.ZhuT.R.Phillips. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol1994; 68: 632–637.
30. A.M.SchwartzM.A.McCrackinR.F.Schinazi. Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells. Am J Vet Res2014; 75: 273–281.
31. R.A.SmithK.M.RemingtonR.M.LloydJr. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol1997; 71: 2357–2362.
32. R.A.SmithK.M.RemingtonB.D.Preston. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2′,3′-dideoxy-3′-thiacytidine and 3′-azido-3′-deoxythymidine. J Virol1998; 72: 2335–2340.
33. N.R.SmythC.McCrackenR.M.Gaskell. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. J Antimicrob Chemother1994; 34: 589–594.
34. A.Tanabe-TochikuraT.S.TochikuraJ.R.BlakesleeJr. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro. Antiviral Res1992; 19: 161–172.
35. T.W.VahlenkampA.De RondeJ.Balzarini. (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother1995; 39: 746–749.
36. Y.Q.ZhuK.M.RemingtonT.W.North. Mutants of feline immunodeficiency virus resistant to 2′,3′-dideoxy-2′,3′-didehydrothymidine. Antimicrob Agents Chemother1996; 40: 1983–1987.
37. K.Hartmann. Feline immunodeficiency virus infection: an overview. Vet J1998; 155: 123–137.
38. M.AraiD.D.EarlJ.K.Yamamoto. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?Vet Immunol Immunopathol2002; 85: 189–204.
39. C.E.GreeneA.D.J.Watson. Antiviral drugs. In: C.E.Greene (ed). Infectious diseases of the dog and cat. 2nd ed.St Louis, MO: Elsevier Saunders, 1998, pp 6–9.
40. E.A.HooverN.S.ZeidnerJ.I.Mullins. Therapy of presymptomatic FeLV-induced immunodeficiency syndrome with AZT in combination with alpha interferon. Ann N Y Acad Sci1990; 616: 258–269.
41. L.E.MathesP.J.PolasK.A.Hayes. Pre- and postexposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother1992; 36: 2715–2721.
42. E.MukherjiJ.L.AuL.E.Mathes. Differential antiviral activities and intracellular metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in human cells. Antimicrob Agents Chemother1994; 38: 1573–1579.
43. L.TavaresC.RonekerK.Johnston. 3′-Azido-3′-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res1987; 47: 3190–3194.
44. L.TavaresC.RonekerL.Postie. Testing of nucleoside analogues in cats infected with feline leukemia virus: a model. Intervirology1989; 30Suppl 1: 26–35.
45. N.S.ZeidnerL.M.RoseC.K.Mathiason-DuBard. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J Acquir Immune Defic Syndr1990; 3: 787–796.
46. N.S.ZeidnerM.H.MylesC.K.Mathiason-DuBard. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother1990; 34: 1749–1756.
47. B.StuetzerK.BrunnerH.Lutz. A trial with 3′-azido-2′,3′-dideoxythymidine and human interferon-alpha in cats naturally infected with feline leukaemia virus. J Feline Med Surg2013; 15: 667–671.
48. E.M.AugustM.E.MarongiuT.S.Lin. Initial studies on the cellular pharmacology of 3′-deoxythymidin-2′-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus. Biochem Pharmacol1988; 37: 4419–4422.
49. M.BabaR.PauwelsP.Herdewijn. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun1987; 142: 128–134.
50. J.BalzariniG.J.KangM.Dalal. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides. Mol Pharmacol1987; 32: 162–167.
51. T.S.LinR.F.SchinaziW.H.Prusoff. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol1987; 36: 2713–2718.
52. J.BalzariniH.EgberinkK.Hartmann. Antiretrovirus specificity and intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5′-monophosphate triester prodrug So324. Mol Pharmacol1996; 50: 1207–1213.
53. H.MitsuyaS.Broder. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA1986; 83: 1911–1915.
54. H.K.MedlinY.Q.ZhuK.M.Remington. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother1996; 40: 953–957.
55. Y.ZhuJ.M.AntonyJ.A.Martinez. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain2007; 130: 2011–2023.
56. S.Broder. Progress in targeted therapy against human immunodeficiency virus [corrected]. Crit Care Med1990; 18: S118–125.
57. P.J.PolasC.L.SwensonR.Sams. In vitro and in vivo evidence that the antiviral activity of 2′,3′-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother1990; 34: 1414–1421.
58. E.A.HooverN.S.ZeidnerN.A.Perigo. Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy. Intervirology1989; 30Suppl 1: 12–25.
59. N.S.ZeidnerJ.D.StrobelN.A.Perigo. Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine. Antiviral Res1989; 11: 147–160.
60. T.CihlarA.S.Ray. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res2010; 85: 39–58.
61. E.De Clercq. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol2007; 73: 911–922.
62. J.BalzariniL.NaesensJ.Slachmuylders. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. Aids1991; 5: 21–28.
63. H.EgberinkM.BorstH.Niphuis. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA1990; 87: 3087–3091.
64. K.HartmannA.DonathB.Beer. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol1992; 35: 167–175.
65. K.HartmannM.KufferJ.Balzarini. Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol1998; 17: 120–128.
66. M.KufferJ.BalzariniB.Rolinski. [Comparative investigation of the efficacy of two nucleocapsid analogs in FIV infected cats.] Tierarztl Prax Ausg K Kleintiere Heimtiere1997; 25: 671–677.
67. M.S.PhilpottJ.P.EbnerE.A.Hoover. Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction. Vet Immunol Immunopathol1992; 35: 155–166.
68. K.HartmannC.StengelD.Klein. Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats. J Vet Intern Med2012; 26: 483–490.
69. E.A.HooverJ.P.EbnerN.S.Zeidner. Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Antiviral Res1991; 16: 77–92.
70. J.BalzariniT.VahlenkampH.Egberink. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrob Agents Chemother1997; 41: 611–616.
71. W.M.Greggs3rdC.L.ClouserS.E.Patterson. Discovery of drugs that possess activity against feline leukemia virus. J Gen Virol2012; 93: 900–905.
72. Q.XiaJ.RadzioK.S.Anderson. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci2007; 16: 1728–1737.
73. K.DasS.E.MartinezJ.D.Bauman. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol2012; 19: 253–259.
74. J.M.Garcia-SchurmannH.SchulzeG.Haupt. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology1999; 53: 535–541.
75. S.BroderR.YarchoanJ.M.Collins. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet1985; 2: 627–630.
76. E.De Clercq. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett1979; 8: 9–22.
77. K.DorfingerB.NiederleH.Vierhapper. Suramin and the human adrenocortex: results of experimental and clinical studies. Surgery1991; 110: 1100–1105.
78. M.KaurE.ReedO.Sartor. Suramin’s development: what did we learn?Invest New Drugs2002; 20: 209–219.
79. B.P.O’DonnellN.A.DawsonR.B.Weiss. Suramin-induced skin reactions. Arch Dermatol1992; 128: 75–79.
80. D.C.CoganS.M.CotterL.W.Kitchen. Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats. Am J Vet Res1986; 47: 2230–2232.
81. J.L.Abkowitz. Retrovirus-induced feline pure red blood cell aplasia: pathogenesis and response to suramin. Blood1991; 77: 1442–1451.
82. C.S.Crumpacker. Mechanism of action of foscarnet against viral polymerases. Am J Med1992; 92: 3S–7S.
83. J.A.StrawT.L.LooC.C.de Vera. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat. J Acquir Immune Defic Syndr1992; 5: 936–942.
84. L.GerardD.Salmon-Ceron. Pharmacology and clinical use of foscarnet. Int J Antimicrob Agents1995; 5: 209–217.
85. A.RyrfeldtT.NordgrenJ.Lundstrom. Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs. Fundam Appl Toxicol1992; 18: 126–130.
86. C.L.SwensonP.J.PolasC.M.Cheney. Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro. Am J Vet Res1991; 52: 2010–2015.
87. S.BeaucourtM.Vignuzzi. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol2014; 8: 10–15.
88. A.LafeuilladeG.HittingerS.Chadapaud. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet2001; 357: 280–281.
89. R.C.Povey. Effect of orally administered ribavirin on experimental feline calicivirus infection in cats. Am J Vet Res1978; 39: 1337–1341.
90. R.C.WeissN.R.CoxM.K.Boudreaux. Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther1993; 16: 301–316.
91. R.C.WeissN.R.CoxM.L.Martinez. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res Vet Sci1993; 55: 162–172.
92. J.RuckerA.L.EdingerM.Sharron. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol1997; 71: 8999–9007.
93. B.J.WillettM.J.Hosie. The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus. Mol Membr Biol1999; 16: 67–72.
94. T.N.WellsA.E.ProudfootC.A.Power. Chemokine receptors – the new frontier for AIDS research. Chem Biol1996; 3: 603–609.
95. B.J.WillettL.PicardM.J.Hosie. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol1997; 71: 6407–6415.
96. G.A.DonzellaD.ScholsS.W.Lin. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med1998; 4: 72–77.
97. H.F.EgberinkE.De ClercqA.L.Van Vliet. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol1999; 73: 6346–6352.
98. D.ScholsJ.A.EsteG.Henson. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res1997; 35: 147–156.
99. W.C.LilesH.E.BroxmeyerE.Rodger. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood2003; 102: 2728–2730.
100. A.Katrin Helfer-HungerbuehlerV.CattoriB.Bachler. Quantification and molecular characterization of the feline leukemia virus A receptor. Infect Genet Evol2011; 11: 1940–1950.
101. V.CattoriB.WeibelH.Lutz. Inhibition of feline leukemia virus replication by the integrase inhibitor Raltegravir. Vet Microbiol2011; 152: 165–168.
102. H.TogamiK.ShimuraM.Okamoto. Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents. J Virol2013; 87: 4322–4329.
103. A.BoeschV.CattoriB.Riond. Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection. Vet Microbiol2015; 175: 167–178.
104. A.DomenechG.MiroV.M.Collado. Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet Immunol Immunopathol2011; 143: 301–306.
105. J.J.StarkR.O.DillmanR.Schulof. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer1998; 82: 1677–1681.
106. S.GilR.O.LealA.Duarte. Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter. Res Vet Sci2013; 94: 753–763.
107. S.GoodbournL.DidcockR.E.Randall. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol2000; 81: 2341–2364.
108. N.GerlachK.GibbertC.Alter. Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol2009; 39: 136–146.
109. E.Gomez-LuciaV.M.ColladoG.Miro. Effect of type-I interferon on retroviruses. Viruses2009; 1: 545–573.
110. K.CantellL.Pyhala. Circulating interferon in rabbits after administration of human interferon by different routes. J Gen Virol1973; 20: 97–104.
111. J.M.CumminsM.W.BeilharzS.Krakowka. Oral use of interferon. J Interferon Cytokine Res1999; 19: 853–857.
112. D.K.KoechA.O.Obel. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). East Afr Med J1990; 67: SS64–70.
113. W.A.Tompkins. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res1999; 19: 817–828.
114. T.TanabeJ.K.Yamamoto. Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma. J Interferon Cytokine Res2001; 21: 1039–1046.
115. E.PedrettiB.PasseriM.Amadori. Low-dose interferon-alpha treatment for feline immunodeficiency virus infection. Vet Immunol Immunopathol2006; 109: 245–254.
116. P.JamesonM.Essex. Inhibition of feline leukemia virus replication by human leukocyte interferon. Antiviral Res1983; 3: 115–120.
117. R.C.WeissJ.M.CumminsA.B.Richards. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc1991; 199: 1477–1481.
118. D.L.McCawG.D.BoonA.E.Jergens. Immunomodulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc2001; 37: 356–363.
119. K.de MariL.MaynardA.Sanquer. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med2004; 18: 477–482.
120. S.GilR.O.LealD.McGahie. Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation. Res Vet Sci2014; 96: 79–85.
121. R.O.LealS.GilA.Duarte. Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega. Res Vet Sci2015; 99: 87–95.
122. R.RogersT.C.MeriganW.D.HardyJr. Cat interferon inhibits feline leukaemia virus infection in cell culture. Nature New Biol1972; 237: 270–271.